Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 17 de 17
Filtrar
Mais filtros










Intervalo de ano de publicação
3.
Dermatol Ther ; 35(7): e15558, 2022 07.
Artigo em Inglês | MEDLINE | ID: mdl-35510581

RESUMO

Hidradenitis suppurativa (HS) is a chronic, inflammatory, and recalcitrant skin disease of the terminal hair follicle. Therapeutic alternatives in HS are limited nowadays. Adalimumab, is the only approved biological treatment for patients with moderate to severe HS, and some patients do not reach an optimal response, or experience a progressive response loss, needing therapeutic alternatives. IL-23 pathway is also involved in HS pathogenesis, so its blockade could contribute to reach disease control. Guselkumab is a monoclonal antibody targeting the p19 subunit of extracellular IL-23, currently approved for psoriasis in adults, and recently some authors have reported its effectiveness in patients with moderate to severe HS refractory to other systemic treatments, becoming a hope for some patients. However adequate dosing and intervals have not been determined yet, so in most published series, doses approved for psoriasis are commonly used. On this topic a retrospective bicentric study including HS patients treated with guselkumab in the dermatologic departments of university hospitals Puerta de Hierro of Majadahonda (Madrid, Spain) and Doctor Peset of Valencia (Valencia, Spain) was conducted. We reported effectiveness, dosage and frequency of administration in the cohort, in order to establish the most effective dosage regimen and to clarify the potential role of guselkumab for this disease.


Assuntos
Anticorpos Monoclonais Humanizados , Hidradenite Supurativa , Psoríase , Adalimumab , Adulto , Anticorpos Monoclonais Humanizados/administração & dosagem , Anticorpos Monoclonais Humanizados/uso terapêutico , Hidradenite Supurativa/diagnóstico , Hidradenite Supurativa/tratamento farmacológico , Humanos , Interleucina-23 , Psoríase/tratamento farmacológico , Psoríase/patologia , Estudos Retrospectivos , Índice de Gravidade de Doença
10.
Rev. senol. patol. mamar. (Ed. impr.) ; 31(4): 152-154, oct.-dic. 2018. ilus
Artigo em Espanhol | IBECS | ID: ibc-176856

RESUMO

El leiomioma del pezón es un tumor benigno y poco frecuente originado a partir de las fibras de músculo liso del tejido subareolar de la mama. Presentamos el caso de un varón con un leiomioma en el complejo areola-pezón izquierdo, destacando las características clínicas e histológicas de estos tumores, así como su manejo


Leiomyoma of the nipple is a rare benign tumour that is thought to arise from smooth muscle fibres in the subareolar tissue of the breast. We report the case of a male patient with a leiomyoma arising from his left nipple-areola complex. The clinical characteristics, gross and microscopic pathologic findings, and management of this lesion are discussed


Assuntos
Humanos , Masculino , Idoso , Leiomioma/patologia , Neoplasias da Mama Masculina/patologia , Mamilos/patologia , Neoplasias Cutâneas/complicações , Diagnóstico Diferencial
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...